1,179
Views
2
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLES: GASTROINTESTINAL TUMORS

Challenges in evaluation of screening for gastric cancer among men based on nonrandomized design

, , , , , & show all
Pages 917-922 | Received 09 Oct 2016, Accepted 28 Dec 2016, Published online: 23 Feb 2017

References

  • Storskrubb T, Aro P, Ronkainen J, et al. Serum biomarkers provide an accurate method for diagnosis of atrophic gastritis in a general population: the Kalixanda study. Scand J Gastroenterol. 2008;43:1448–1455.
  • Miki K, Morita M, Sasajima M, et al. Usefulness of gastric cancer screening using the serum pepsinogen test method. Am J Gastroenterol. 2003;98:735–739.
  • Dinis-Ribeiro M, Yamaki G, Miki K, et al. Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening. J Med Screen. 2004;11:141–147.
  • Sackett DL, Holland WW. Controversy in the detection of disease. Lancet. 1975;2:357–359.
  • Teppo L, Pukkala E, Lehtonen M. Data quality and quality control of a population-based cancer registry. Experience in Finland. Acta Oncol. 1994;33:365–369.
  • Ahrens W, Pigeot I, editors. Handbook of epidemiology. Berlin: Springer; 2005.
  • Cambell DT, Stanley JC. Experimental and quasi-experimental designs for research. Chicago (IL): Rand McNally; 1966.
  • Cochrane AL, Holland WW. Validation of screening procedures. Br Med Bull. 1971;27:3.
  • Holland WW, Steward S. Screening in health care. London: The Nuffield Provincial Hospitals Trust; 1990.
  • Engholm G, Ferlay J, Christensen N, et al. Gastric precancerous process in a high risk population: cohort follow-up. Cancer Res. 1990;50:4737–4740.
  • Correa P, Piazuelo MB. The gastric precancerous cascade. J Dig Dis. 2012;13:2–9.
  • Haenszel W, Correa P, Cuello C, et al. Gastric cancer in Colombia. II. Case-control epidemiologic study of precursor lesions. J Natl Cancer Inst. 1976;57:1021–1026.
  • Sipponen P, Kekki M, Haapakoski J, et al. Gastric cancer risk in chronic atrophic gastritis: statistical calculations of cross-sectional data. Int J Cancer. 1985;35:173–177.
  • Varis K, Sipponen P, Laxen F, et al. The Helsinki Gastritis Study Group. Implications of serum pepsinogen I in early endoscopic diagnosis of gastric cancer and dysplasia. Scand J Gastroenterol. 2000;35:950–956.
  • Jang JS, Choi SR, Qureshi W, et al. Long-term outcomes of endoscopic submucosal dissection in gastric neoplastic lesions at a single institution in South Korea. Scand J Gastroenterol. 2009;44:1315–1322.
  • De Vries AC, Kuipers EJ. Epidemiology of premalignant gastric lesions: implications for the development of screening and surveillance strategies. Helicobacter. 2007;12:22–31.
  • Crumley AB, Going JJ, McEwan K, et al. Endoscopic mucosal resection for gastroesophageal cancer in a U.K. population. Long-term follow-up of a consecutive series. Surg Endosc. 2011;25:543–548.
  • Ichinose M, Yahagi N, Oka M, et al. Screening for gastric cancer in Japan. In: Wu GY, Aziz K, editors. Cancer screening. A practical guide for physicians. Potowa (NJ): Humana Press; 2001. p. 87–102.
  • Benichou J, Palta M. Rates, risks, measures of association and impact. In: Ahrens W, Pigeot I, editors. Handbook of epidemiology. Berlin: Springer; 2005. p. 8–146.
  • Wilson JMG, Junger G. Principles and practice of screening for disease. Public Health Paper Number 34. Geneva: WHO; 1968.